Advances in Pancreatic Cancer Treatment
Author Information
Author(s): DD Von Hoff, AL Goodwin, L Garcia, The San Antonio Drug Development Team
Primary Institution: Institute for Drug Development, Cancer Therapy & Research Center
Hypothesis
Can gemcitabine improve symptoms and survival time in patients with pancreatic cancer?
Conclusion
Gemcitabine is the first new agent shown to improve symptoms and survival in patients with advanced pancreatic cancer.
Supporting Evidence
- 23.8% of gemcitabine-treated patients experienced clinical benefit compared to 4.8% of those treated with 5-FU.
- Median survival was 5.65 months for gemcitabine patients versus 4.41 months for 5-FU patients.
- Patients with clinical benefit had a longer time until disease progression.
Takeaway
Gemcitabine helps people with pancreatic cancer feel better and live longer.
Methodology
A randomized trial comparing gemcitabine to 5-fluorouracil in patients with advanced pancreatic cancer.
Limitations
The study was not double-blinded due to safety concerns.
Participant Demographics
Patients with advanced pancreatic cancer, no prior chemotherapy, and measurable lesions.
Statistical Information
P-Value
0.0022
Statistical Significance
p=0.0022
Want to read the original?
Access the complete publication on the publisher's website